Seegene, a company in molecular diagnostics, announced it will unveil its fully automated PCR testing system, CURECA, and data analytics platform, STAgora, at ADLM 2025, the Association for Diagnostics & Laboratory Medicine’s annual conference in Chicago from July 28 to 31.
The new technologies are positioned to support a shift in laboratory workflows and clinical diagnostics. CURECA is designed to automate the complete PCR testing cycle—from sample storage and pre-treatment to nucleic acid extraction, amplification, and result analysis—without requiring manual intervention. Intended for continuous 24/7 use, the system is built to reduce human error and improve consistency.
A central feature of the system is its fully automated pre-treatment module, which addresses key inefficiencies in current lab processes. Manual pre-treatment, especially with diverse samples like urine, blood, sputum, and stool, has traditionally led to inconsistent outcomes due to human variability and the complexity of the sample matrix. The CURECA prep module automates this process across all major sample types, including stool, which has historically been a barrier to automation due to its high viscosity and particulate content.
This automation reduces manual labour, increases sample throughput, and supports a shift in lab personnel roles from repetitive handling to data analysis and clinical interpretation. The prep module is also applicable to clinical chemistry and immunoassay workflows, broadening its use across diagnostic disciplines. Its modular architecture allows adaptation to individual lab needs.
Seegene will also introduce STAgora, a statistical data platform that compiles and analyses real-time PCR diagnostic data to inform clinical decision-making. The platform collects results from hospitals worldwide and provides insights into regional infection trends, hospital positivity rates, and co-infection patterns. It includes over 40 tools developed for clinical support.
By allowing comparisons between individual patient results and broader epidemiological data, STAgora supports targeted treatment approaches. Clinicians can monitor both patient and community-level infection trends, helping improve diagnosis and care planning.
Seegene is aiming to expand access to CURECA and STAgora through pilot programmes and new partnerships. Earlier this year, CURECA was presented at ESCMID Global 2025 and drew interest across the European diagnostics sector. The company has also expanded its operations in the United States through subsidiaries such as Seegene Technologies and Seegene CURECA.
“CURECA and STAgora are more than just diagnostics instrument or software—they represent a new global standard that will redefine diagnostics in clinical settings around the world. We will continue to share the many technological assets we’ve built over the years and based on this, we are committed to driving fundamental innovation across the global diagnostics ecosystem,” said Daniel Shin, Executive Vice President, Chief of Global Sales & Marketing at Seegene.